2012
DOI: 10.1016/j.nec.2012.06.011
|View full text |Cite
|
Sign up to set email alerts
|

External Beam Radiation Therapy and Stereotactic Radiosurgery for Pituitary Adenomas

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
30
0
1

Year Published

2013
2013
2019
2019

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 28 publications
(31 citation statements)
references
References 84 publications
0
30
0
1
Order By: Relevance
“…RT is used where surgery is contraindicated and for recurrence or progression of non-secreting adenomas or hormonally uncontrolled tumours after maximal surgical and medical therapy [29,30]. Over the past decade, stereotactic radiosurgery (SRS), delivering a large single dose of highly collimated radiation and fractionated stereotactic RT (FRST) delivered over 5-6 weeks, with higher precision and less tissue damage but requiring a longer period to achieve biochemical normalisation, has emerged [29,30].…”
Section: Management Of Ppasmentioning
confidence: 99%
“…RT is used where surgery is contraindicated and for recurrence or progression of non-secreting adenomas or hormonally uncontrolled tumours after maximal surgical and medical therapy [29,30]. Over the past decade, stereotactic radiosurgery (SRS), delivering a large single dose of highly collimated radiation and fractionated stereotactic RT (FRST) delivered over 5-6 weeks, with higher precision and less tissue damage but requiring a longer period to achieve biochemical normalisation, has emerged [29,30].…”
Section: Management Of Ppasmentioning
confidence: 99%
“…Its rate of remission and side-effect profile are superior to those for fractionated radiation therapy. 9 Tumor control after GKS is greater than 90% in most functioning adenoma series. 2,5,[7][8][9] However, endocrine remission rates vary from 40% to 80%.…”
Section: Disclosurementioning
confidence: 99%
“…9 Tumor control after GKS is greater than 90% in most functioning adenoma series. 2,5,[7][8][9] However, endocrine remission rates vary from 40% to 80%. 2,5,[7][8][9] This disparity between tumor control and endocrine remission underscores an opportunity for significant improvement in outcomes.…”
Section: Disclosurementioning
confidence: 99%
See 2 more Smart Citations